Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has Aurora Spine's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AROS.F has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: AROS.F underperformed the US Medical Equipment industry which returned 16.2% over the past year.
Return vs Market: AROS.F underperformed the US Market which returned 14.2% over the past year.
Price Volatility Vs. Market
How volatile is Aurora Spine's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Aurora Spine undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: AROS.F ($0.19) is trading above our estimate of fair value ($0.1)
Significantly Below Fair Value: AROS.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AROS.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: AROS.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AROS.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AROS.F is good value based on its PB Ratio (3.7x) compared to the US Medical Equipment industry average (4x).
How is Aurora Spine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aurora Spine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Aurora Spine's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Aurora Spine's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
How has Aurora Spine performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AROS.F is currently unprofitable.
Growing Profit Margin: AROS.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AROS.F is unprofitable, but has reduced losses over the past 5 years at a rate of 35.3% per year.
Accelerating Growth: Unable to compare AROS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AROS.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: AROS.F has a negative Return on Equity (-52.31%), as it is currently unprofitable.
How is Aurora Spine's financial position?
Financial Position Analysis
Short Term Liabilities: AROS.F's short term assets ($5.4M) exceed its short term liabilities ($2.1M).
Long Term Liabilities: AROS.F's short term assets ($5.4M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: AROS.F's debt to equity ratio (73.5%) is considered high.
Reducing Debt: Insufficient data to determine if AROS.F's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AROS.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AROS.F is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 53.9% per year.
What is Aurora Spine current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AROS.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AROS.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AROS.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AROS.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AROS.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Trent Northcutt (53 yo)
Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. He is a Founder of Aurora Spine Corporation. Mr. Northcutt served as Vice President at S ...
CEO Compensation Analysis
Compensation vs Market: Trent's total compensation ($USD143.04K) is below average for companies of similar size in the US market ($USD594.44K).
Compensation vs Earnings: Trent's compensation has been consistent with company performance over the past year.
|Independent Chairman||4.92yrs||US$20.28k||15.95% |
|Independent Director||7.17yrs||US$2.02k||0.13% |
|Independent Director||7.17yrs||US$1.98k||0.71% |
|Independent Director||7.17yrs||US$2.50k||1.98% |
|Independent Director||7.17yrs||US$1.73k||0.18% |
Experienced Board: AROS.F's board of directors are considered experienced (7.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.3%.
Aurora Spine Corporation's company bio, employee growth, exchange listings and data sources
- Name: Aurora Spine Corporation
- Ticker: AROS.F
- Exchange: OTCPK
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CA$14.407m
- Listing Market Cap: CA$10.942m
- Shares outstanding: 55.41m
- Website: https://www.aurora-spine.com
- Aurora Spine Corporation
- 20 Holly Street
- Suite 300
- M4S 3B1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ASG||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Sep 2013|
|AROS.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Sep 2013|
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. The company offers interspinous process lumbar fusion devices for patients ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/18 05:58|
|End of Day Share Price||2020/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.